Chemistry:LSR-3000

From HandWiki

LSR-3000 is a non-selective serotonin receptor agonist and psychoplastogen of the tryptamine family which is under development for the treatment of neurological disorders.[1][2][3] The drug is taken by mouth.[1] It is under development by Lusaris Therapeutics.[1][2][3] As of November 2022, LSR-3000 is in the research or discovery stage of development.[1][2][3] Its chemical structure does not yet appear to have been disclosed.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "LSR 3000". 16 November 2022. https://adisinsight.springer.com/drugs/800070857. "LSR 3000 is a small molecule, serotonergic neuroplasogen therapeutic being developed by Lusaris Therapeutics, for the treatment of neuropsychiatric and [...]" 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on LSR-3000 with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/008221fdcd8f4cb1abfd8e5b95647dfc. 
  3. ↑ 3.0 3.1 3.2 "Psychedelic startup launches with $60m and Catalent tech". OutsourcingPharma. 14 November 2022. https://www.outsourcing-pharma.com/Article/2022/11/14/psychedelic-startup-launches-with-60m-and-catalent-tech/. "Alongside LSR-1019, the biotech also has LSR-2000 in a late-stage discovery program evaluating serotonergic neuroplastogens for the prevention of migraines and cluster headaches. In addition, LSR-3000 is at the discovery phase for developing therapies suitable for chronic dosing by maintaining broad serotonergic receptor activation." 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:LSR-3000&oldid=4035900"